24/7
Buzz
Startups
VC
AI
Innovation
Opinions
Events
Promising Startups 2024
BiblioTech
Boarding Pass
Corporate
Appointments
CTalk
Tech Gateways
2025 VC survey
@Finance
Ctech Testimonials
Shopping
Projects
About
Newsletter
Contact us
RSS
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Divestment
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
Innovation
OPINIONS
EVENTS
SHOPPING
ABOUT
Terms Of Use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
16:00
Spot.io founder nets $7 million Seed round to tackle cloud chaos with new startup
16:00
Reeco raises $15M Series A to modernize hotel procurement
15:39
Qualcomm Ventures: Not every “AI” technology is actually AI
14:38
"The world still sees the core advantage Israel has and appreciates it"
More stories
Buzz
Most popular
Daily
Weekly
1
Orchid raises $36 million Seed round to automate enterprise identity security with AI
2
Mapping Israeli open source startups
3
Blockchain giant Chainalysis acquires Israeli startup Alterya in $150M deal
4
Israeli VCs find opportunity in adversity, betting big on 2025
5
Israel faces AI crisis under new US export regulations
More news
Divestment
6 stories about Divestment
With No Buyers, Teva to Close Israeli Medical Equipment Plant
09.04.18
|
Dror Reich
The facility in Ashdod is one of five Teva intends to sell or close in its home country
Allergan to Sell Teva Shares to J.P. Morgan
14.11.17
|
Dror Reich and Lilach Baumer
Allergan announced it pledged its 9.8% stake in Teva to J.P. Morgan as collateral, as part of a loan agreement. The company already agreed to sell a quarter of the stock in the first quarter of 2018
Teva Offloads Holdings in Australia’s Mesoblast
25.10.17
|
Dror Reich and Lilach Baumer
The stem-cell therapy company diluted Teva’s shares through a new offering in August
Founding Family Sells Holdings in Online Gambling Company 888
09.10.17
|
Golan Hazani and Lilach Baumer
Co-founder Aaron Shaked’s heirs sold their entire stake for nearly $300 million
Teva Sells Remaining Women's Health Assets
18.09.17
|
Lilach Baumer
After selling its Paragard business for $1.1 billion last week, Teva's remaining Women's Health business will be split between CVC Capital Partners and Foundation Consumer Healthcare in a $1.38 billion cash deal
Teva Negotiating Sale of Remaining Women's Health Assets, Report Says
14.09.17
|
Lilach Baumer
CVC Capital Partners is nearing a $800 million deal for Teva's remaining Women's Health business, Bloomberg reported Thursday
Please ensure Javascript is enabled for purposes of
website accessibility